Spyre Therapeutics is a clinical-stage biotechnology company developing antibody therapies for inflammatory bowel disease and other immune-mediated conditions.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Andrew Law / Caxton | 64 | New buy | 8,919 | $292,194 | 6.8% |
| Carlyle Group Inc. (auto-surfaced) | 48 | New buy | 9,620 | $315,055 | 0.0% |
| Filed | Form | Activist | % of class | Conviction | |
|---|---|---|---|---|---|
| 2026-04-20 | SCHEDULE 13D/A | Fairmount Funds Management LLC | 10.0% | High | filing |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.